Knowledge-map analysis of bladder cancer immunotherapy

Figures & data

Figure 1. Flow chart of the literature screening related to BC immunotherapy research.

Figure 2. Annual number of publications in BC immunotherapy from 2000 to 2022.

Table 1. Top 10 most active countries/regions of BC immunotherapy.

Rank	Country	Number of publications	Count of citations
1	USA	627	27,308
2	Peoples r china	509	6,313
3	Japan	163	4,089
4	Germany	161	8,960
5	Italy	160	4,992
6	France	146	9,462
7	England	118	6,905
8	Spain	111	8,068
9	Canada	103	2,808
10	Netherlands	98	7,576

Figure 3. Bibliometric analysis of the co-authorship of countries/regions in the field of BC immunotherapy. (a) Network visualization map of countries/regions collaborations in the field of BC immunotherapy. (b) Overlay visualization map of countries/regions collaborations in the field of BC immunotherapy.

Table 2. Top 10 most active institutions related to BC immunotherapy.

Rank	Institution	Number of publications	Count of citations	Country
1	Univ of texas md anderson canc ctr	58	2,721	USA
2	Mem sloan kettering canc ctr	52	3,393	USA
3	Univ iowa	49	1,951	USA
4	Shanghai jiao tong univ	49	660	Peoples r china
5	Fudan univ	41	423	Peoples r china
6	Cent south univ	31	457	Peoples r china
7	Harvard med sch	29	667	USA
8	Southern med univ	29	244	Peoples r china
9	Sichuan univ	28	228	Peoples r china
10	Mayo clin	26	2,947	USA

Figure 4. Bibliometric analysis of the co-authorship of institutions in the field of BC immunotherapy. (a) Network visualization map of collaborations among institutions in the field of BC immunotherapy. (b) Overlay visualization map of collaborations among institutions in the field of BC immunotherapy.

Figure 5. Bibliometric analysis of the co-cited authors and co-authorship of authors in the field of BC immunotherapy. (a) Density visualization map of co-cited authors in the field of BC immunotherapy. (b) Network visualization map of authors collaboration in the field of BC immunotherapy. (c) Overlay visualization map of authors collaboration in the field of BC immunotherapy.

Table 3. Top 10 most active authors and co-cited authors related to BC immunotherapy.

Rank	Author	Number of publications	Count of citations	Co-cited Author	Count of co-citation
1	Kamat, AM	28	980	Lamm, DL	980
2	Necchi, A	25	890	Powles, T	552
3	O’donnell, MA	22	657	Sylvester, RJ	535
4	Zhu Yu	20	249	Bellmunt, J	503
5	Chang Yuan	19	254	Herr, HW	496
6	Xu Le	19	254	Morales, A	421
7	Wang Zewei	18	209	Babjuk, M	402
8	Zeng Han	18	209	Sharma, P	399
9	Galsky, MD	18	776	Bohle, A	393
10	Xu Jiejie	17	189	Witjes, JA	369

Table 4. Top 10 most active journals related to BC immunotherapy.

Rank	Journal	Number	Country	Citation	IF(2022)	Journal Citation Reports (JCR)
1	J UROLOGY	100	USA	8,028	6.6	Q1
2	UROL ONCOL-SEMIN ORI	82	USA	1,201	2.7	Q3
3	EUR UROL	71	Netherlands	7,525	23.4	Q1
4	FRONT ONCOL	55	Switzerland	481	4.7	Q2
5	FRONT IMMUN	50	Switzerland	396	7.3	Q1
6	BJU INT	45	English	1,510	4.5	Q1
7	CANCER IMMUNOL IMMUN	43	USA	1,277	5.8	Q1
8	UROLOGY	39	USA	1,323	2.1	Q3
9	WORLD J UROL	37	USA	970	3.4	Q2
10	CANCERS	35	USA	212	5.2	Q1

Figure 6. Bibliometric analysis of co-cited journals in the field of BC immunotherapy. (a) Density visualization map of co-cited journals in the field of BC immunotherapy. (b) Top 10 main co-cited journals related to BC immunotherapy.

Figure 7. Density visualization map of co-cited references in the field of BC immunotherapy.

Table 5. Top 10 co-cited references related to BC immunotherapy.

Rank	Article title	Corresponding author	Country	Year	Count	Journal	IF(2022)
1	Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors	Morales, A	Canada	1976	275	J UROLOGY	6.6
2	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial	Rosenberg, JE	USA	2016	247	LANCET	168.9
3	Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study	Lamm, DL	USA	2000	225	J UROLOGY	6.6
4	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma	Bellmunt, J	USA	2017	195	NEW ENGL J MED	158.5
5	Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials	Sylvester, RJ	Belgium	2002	158	J UROLOGY	6.6
6	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial	Balar, AV	USA	2017	157	LANCET	168.9
7	Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials	Sylvester, RJ	Belgium	2006	152	EUR UROL	23.4
8	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial	Sharma, P	USA	2017	147	LANCET ONCOL	51.1
9	TGFβ attenuates tumor response to PD-L1 blockade by contributing to exclusion of T cells	Mariathasan, S	USA	2018	137	NATURE	168.9
10	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer	Robertson, AG	Canada	2017	134	CELL	64.5

Figure 8. Bibliometric analysis of the co-occurrence of all keywords in the field of BC immunotherapy. (a) Network visualization map of high frequency keywords in the field of BC immunotherapy. (b) Overlay visualization map of high frequency keywords in the field of BC immunotherapy.